James Orford, MD
Cardiovascular Disease · Murray, UTNPI 1902843931
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,271 of the $1,979 with a category attached, or 64.2%. Heartflow, Inc. accounts for 92.4% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2022 at $1,659 and has fallen 89.7% since, to $171 in 2023.
Across 8 payments — averaging $247.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Heartflow, Inc.$2K
- Abbott$149
Across 5 payments — averaging $19,197 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$93K
- W. L. Gore & Associates, Inc.$3K
What the payments were for
- Consulting fees$322%
- Travel & lodging$1,27164%
- Food & beverage$67634%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Heartflow, Inc. | 7 | $1,830 |
| Abbott | 1 | $149 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FFRct$1,737
- Mitra Clip system$149
How this compares
$1,979 in reported general payments places this provider in the 55th percentile of 131 cardiovascular disease providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 31 | $37,633 |
| Ezetimibe | 44 | $1,661 |
| Metoprolol Succinate | 108 | $1,624 |
| ClopidogrelClopidogrel Bisulfate | 77 | $1,225 |
| Atorvastatin Calcium | 77 | $1,024 |
| Losartan Potassium | 62 | $780 |
| Rosuvastatin Calcium | 47 | $683 |
| Carvedilol | 39 | $631 |
| Potassium Chloride | 23 | $614 |
| Amlodipine Besylate | 32 | $403 |
| Metoprolol Tartrate | 30 | $354 |
| Hydrochlorothiazide | 34 | $284 |
| Lisinopril | 22 | $246 |
| Furosemide | 34 | $230 |
| Spironolactone | 16 | $230 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Murray
- Brian WhisenantMurray$416K
- Joseph MuhlesteinMurray$65K
- Divya Ratan VermaMurray$47K
- Kirk KnowltonMurray$18K
- Stephen MillerMurray$11K
- Travis MossMurray$6K
- Jonathan HarrisonMurray$5K
- Alpana SenapatiMurray$4K
- Kia AfsharMurray$4K
- Gary SymkoviakMurray$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.